SAb Biotherapeutics, Inc.
SAb Biotherapeutics develops SAB-142, a fully human anti-thymocyte globulin in clinical development for autoimmune type 1 diabetes.
10-QNov 5Latest SEC filing
Oct 13Latest story
October 2026
Sign inSign inSAb Biotherapeutics develops SAB-142, a fully human anti-thymocyte globulin in clinical development for autoimmune type 1 diabetes.